A Study of LY2940094 in Participants With Alcohol Dependency

Status:	Completed
Conditions:	Psychiatric
Therapuetic Areas:	Psychiatry / Psychology
Healthy:	No
Age Range:	21 - 65
Updated:	5/3/2014
Start Date:	July 2013
End Date:	June 2014
Contact:	There may be multiple sites in this clinical trial 1-877-CTLILLY (1-877-285-4559) or
Phone:	1-317-615-4559

Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial in Patients With Alcohol Dependence

The main purpose of this study is to evaluate a once daily (QD) 40 milligram (mg) oral dose
of LY2940094 in participants with an alcohol dependency to evaluate if LY2940094 will reduce
alcohol drinking in these participants. The study will last for 8 weeks.

Inclusion Criteria:

- Present with alcohol dependence (AD) defined by the Diagnostic and Statistical Manual
of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR 303.9)

- Must have 3 to 6 heavy drinking days per week as assessed by the Timeline Follow Back
(TLFB) scale at screening and baseline (heavy drinking is defined as greater than 4
drinks per day for females and greater than 5 drinks per day for males)

- Have a body mass index (BMI) between 18 and 35 kilograms per square meter (kg/m^2)

Exclusion Criteria:

- Have had prior seizures or other condition that would place the participant at
increased risk of seizures, and participants taking anticonvulsants for seizure
control

- Have any other clinically significant medical condition or circumstance prior to
randomization that, in the opinion of the investigator, could affect participant
safety

- Meet Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, (DSM-IV)
Axis I criteria for a lifetime diagnosis of schizophrenia, schizoaffective disorder,
bipolar I disorder, or other psychoses

We found this trial at

sites

Clinical Trial Facility in Portland Oregon

Portland, Oregon

from

Portland, OR